CONGRESS COVERAGE: EHA 2020 – FOCUS ON LEUKEMIA AND MDS

Clinical trials updates, emerging therapies, and future directions in acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML)

Faculty Co-Chair

Dieter Hoelzer, MD, PhD Aptitude Health EPICS Leukemia

Dieter Hölzer, MD, PhD

University of Frankfurt, Frankfurt, Germany

Faculty Co-Chair

Elias Jabbour MD Anderson Cancer Center Aptitude Health

Elias Jabbour, MD

University of Texas MD Anderson Cancer Center, Houston, TX, USA

DOWNLOAD THE DRAFT AGENDA

This agenda is preliminary. Discussion topics may change depending on the final EHA abstract selection. To download the draft agenda for this meeting:

Report Topics Include

  • MDS
  • Elderly/Unfit AML Patients
  • IDH– and FLT3-Mutant AML Patients
  • Emerging Immune Therapies in AML
  • Updates in ALL
  • Strategic Insights and Key Takeaways

Co-Chairs

Dieter Hölzer, MD, PhD
University of Frankfurt, Frankfurt, Germany

Elias Jabbour, MD
University of Texas MD Anderson Cancer Center, Houston, TX, US

 

Faculty Members

Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, US

Naval Daver, MD
University of Texas MD Anderson Cancer Center, Houston, TX, US

Gert Ossenkoppele, MD, PhD
VU Medical Center, Amsterdam, The Netherlands

Josep-Maria Ribera, MD, PhD
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

Valeria Santini, MD
University of Florence, Florence, Italy

Jorge Sierra, MD, PhD
Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

Explore Available and Upcoming Insight Reports

View Reports